[1]邵礼成,菅洪健,陈广辉,等.中青年分化型甲状腺癌患者术后复发与生存分析[J].南方医科大学学报,2017,(02):274.
点击复制

中青年分化型甲状腺癌患者术后复发与生存分析()
分享到:

《南方医科大学学报》[ISSN:/CN:]

卷:
期数:
2017年02期
页码:
274
栏目:
出版日期:
2017-01-22

文章信息/Info

Title:
Recurrence and survival analysis of postoperative patients aged 25 to 59 years with differentiated thyroid carcinoma
作者:
邵礼成菅洪健陈广辉梁蕴谊黄文柱
关键词:
甲状腺癌分化型中青年生存分析生存率
Keywords:
thyroid carcinoma differentiated young and middle-aged survival analysis survival rates
摘要:
目的探讨中青年分化型甲状腺癌患者术后复发情况与生存情况。方法回顾性分析1996~2011年间我院随访36例分化 型甲状腺癌患者的临床资料,记录复发情况和生存状态,采用Kaplan-Meier法分析不同因素下的生存情况。结果共有9例患 者死于复发或转移,首次手术至复发的区间为22~46 个月;以上36 例患者的生存区间为34~135+个月(删失),10 年生存率为 75.0%;Kaplan-Meier分析显示:男性分化型甲状腺癌患者中位生存期明显短于女性(χ2=3.164,P=0.041),45~59岁组的中位生 存期明显短于25~44岁组(χ2=4.622,P=0.032),术后接受131I治疗患者中位生存期显著长于未接受者(χ2=4.527,P=0.033),而是 否行甲状腺全切除对中位生存期无明显影响(χ2=0.988,P=0.320),不同临床分期亦对中位生存期无明显影响(χ2=2.2132,P= 0.167)。结论术后2~4年内是中青年分化型甲状腺癌患者术后复发的高峰期;未行131I治疗的45~59岁男性患者具有较高的复 发风险,以上对临床决策具有重要指导作用。
Abstract:
Objective To investigate the recurrence and survival of postoperative patients with differentiated thyroid carcinoma (DTC) aged from 25 to 59 years. Methods We retrospectively analyzed the clinical data of 36 patients with DTC treated in our hospital from 1996 to 2011, and the recurrence and survival status of the patients were recorded. Kaplan-Meier analysis was carried out to analyze factors that affect the patient’s survival. Results Nine patients died of recurrence or metastasis, and the interval between the initial surgery and recurrence ranged from 22 to 46 months. The survival time of the 36 patients ranged from 34 to 135 months with a 10-year survival rate of 75.0% . Kaplan-Meier analysis showed that male patients had a significantly shorter mean survival time than female patients (χ2=3.164, P=0.041); the median survival time of patients aged 45-59 years was obviously shorter than that of patients aged 25-44 years (χ2=4.622, P=0.032); the postoperative survival in patients with 131I therapy was significantly longer than those who did not receive the therapy (χ2=4.527, P=0.033), and was not affected by total excision of the thyroid gland (χ2=0.988, P=0.320). No significant difference was found in the median survival of patients in different clinical stages (χ2=2.2132, P=0.167). Conclusion In young and middle-aged patients with DTC, postoperative recurrence is the most likely in 2 to 4 years after the surgery. Male patients at 45-59 years of age who do not receive 131I treatment are at high risks of tumor recurrence.

相似文献/References:

[1]薛刚,刘军超,黄静,等.血清与组织glactin-3联合检测在甲状腺癌早期诊断中的价值[J].南方医科大学学报,2013,(07):1027.
[2]史琳,张安文,罗宇,等.细胞周期正性调控因子的异常表达与甲状腺癌发生发展的关系[J].南方医科大学学报,2013,(07):1031.

更新日期/Last Update: 1900-01-01